The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|October 24, 2019
Routine Shutdown of Lonza Site Announced
Author(s)Pharmaceutical Technology Editors
Lonza has announced that its Niacinamide Plant in Nansha, China will be shut down in November and December 2019 for routine maintenance.
Advertisement
Lonza has announced that its Niacinamide Plant in Nansha, China will be shut down in November and December 2019 for routine maintenance. The Nansha site is the production plant for Niacinamide (vitamin B3), a product that is mainly exported to European countries, the Americas, Japan, and Australia, as well as the Chinese market. The routine maintenance and process optimization is expected to take six weeks at the end of the year, the company stated in an Oct. 22, 2019 press release.
In the press release, Lonza confirmed that during the showdown period it will fulfill all orders and contractual obligations.
Source:
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
AI Formulation: Regulators Want Data
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5